Impact of the ONCOBIOME network in cancer microbiome research
Open accessThe DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index; 57 of the 170 sources its claims cite were checked for support.
Abstract
The European Union-sponsored ONCOBIOME network has spurred an international effort to identify and validate relevant gut microbiota-related biomarkers in oncology, generating a unique and publicly available microbiome resource. ONCOBIOME explores the effects of the microbiota on gut permeability and metabolism as well as on antimicrobial and antitumor immune responses. Methods for the diagnosis of gut dysbiosis have been developed based on oncomicrobiome signatures associated with the diagnosis, prognosis and treatment responses in patients with cancer. The mechanisms explaining how dysbiosis compromises natural or therapy-induced immunosurveillance have been explored. Through its integrative approach of leveraging multiple cohorts across populations, cancer types and stages, ONCOBIOME has laid the theoretical and practical foundations for the recognition of microbiota alterations as a hallmark of cancer. ONCOBIOME has launched microbiota-centered interventions and lobbies in favor of official guidelines for avoiding diet-induced or iatrogenic (for example, antibiotic- or proton pump inhibitor-induced) dysbiosis. Here, we review the key advances of the ONCOBIOME network and discuss the progress toward translating these into oncology clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
30 Valid · 5 Not valid · 67 Not checked · 19 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“By contrast, fecal detection of oral taxa, species from the immunosuppressive Enterocloster genus or Hungatella hathewayi was associated with therapeutic resistance 36”
§ Impact of the ONCOBIOME network in cancer microbiome research > Pan-cancer meta-analysis
What the sources say
- Supportedcites [36] Thomas, A. M. et al. Gut oncomicrobiome signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 583–603 (2023). source
In “GOMS and prediction of response to ICIs,” the paper reports a stool-based analysis in which non-responder signatures included Enterocloster, Hungatella hathewayi, and the oral genera Streptococcus and Actinomyces. This supports the association with resistance to immune checkpoint inhibitors; it does not imply that the bacteria cause resistance. (LLM, conf=0.93)
plainstates an associationn = 808- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“revealed limited reproducibility of metastatic melanoma GOMS across distinct publicly available datasets 19,38”
§ Impact of the ONCOBIOME network in cancer microbiome research > Metastatic melanoma
What the sources say
- Supportedcites [19] McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545–556 (2022). source
The Discussion (page not available) says models trained on individual melanoma cohorts failed to predict response in other cohorts, citing cohort heterogeneity, while meta-analysis largely confirmed broader microbial associations. The Results, “Gut microbiome composition predicts clinical response” (page not available), likewise reports variable cross-cohort performance. This supports limited reproducibility of cohort-specific gut microbiome signatures, though the paper also reports improved prediction using pooled, batch-corrected data. (LLM, conf=0.90)
- Supportedcites [38] Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535–544 (2022). source
The Results section ('Limited reproducibility of response predictions across cohorts') reports that microbiome-based predictions of immunotherapy response had limited cross-cohort consistency, including across publicly available melanoma datasets. The Discussion likewise reports no taxonomic or functional microbiome biomarkers consistent across all datasets. (LLM, conf=0.91)
plainn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of note, the frequency of apoptotic enterocytes detectable in the ileum (but not in the colon) correlated with favorable prognosis in patients with right colon cancer receiving oxaliplatin-based chemotherapy 30”
§ Impact of the ONCOBIOME network in cancer microbiome research > Diagnosis of gut dysbiosis: from GOMS to the TOPOSCORE
What the sources say
- Partly supportedcites [30] Roberti, M. P. et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat. Med. 26, 919–931 (2020). sourceExperimental — accuracy not yet measured
Our copy supports the ileum-versus-colon contrast and the direction of the association: apoptosis was induced by chemotherapy 'only in the crypts of ilea, but not in the villi, lamina propria or healthy colons adjacent to tumors' (Ileal apoptosis dictates the prognosis…, Fig. 1a,b), and higher cCasp3 density in ileal crypts segregated PFS (Fig. 1 log-rank P = 0.05 for ileum vs P = 0.20 for colon). However, the prognostic correlation is attributed to a different patient subset than the claim states: the main text says 'higher BASELINE levels of cCasp3 in ileal crypts (≥ median value) were associated with favorable prognosis in patients with stage IV pCC in univariate analyses (Fig. 1c)', and the Fig. 1c legend specifies 'patients with NONTREATED stage IV pCC from the validation cohort (ileum n = 18, colon n = 13)'. Thus the claim's qualifier 'receiving oxaliplatin-based chemotherapy' is not what the source reports, and the restriction to stage IV proximal (right) colon cancer is dropped; oxaliplatin preconditioning in the paper concerns the induction of ileal crypt apoptosis and its immunogenicity (mouse/avatar work), not the patient survival association. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“such as the genus Enterocloster”
- Also stated in: § Immunogenic versus tolerogenic microorganisms · plain
“H. hathewayi, which compromise the efficacy of ICB 29,30”
§ Impact of the ONCOBIOME network in cancer microbiome research > Immunogenic versus tolerogenic microorganisms
What the sources say
- Partly supportedcites [29] Yonekura, S. et al. Cancer induces a stress ileopathy depending on β-adrenergic receptors and promoting dysbiosis that contributes to carcinogenesis. Cancer Discov. 12, 1128–1151 (2022). sourceExperimental — accuracy not yet measured
Our copy supports the H. hathewayi component: in 'Significance of Intestinal Dysbiosis in Cancer' the authors gavaged tumor-bearing mice receiving anti-PD-1 mAb with Clostridia spp. associated with antibiotic- and tumor-induced immunosuppression, including C./Hungatella hathewayi and C. clostridioforme, and this 'significantly compromised the efficacy of the immunotherapy' (whereas Lactobacillus reuteri did not). However, the genus name Enterocloster never appears anywhere in our copy (searched: Enterocloster, Enterocloster bolteae/clostridioforme); the human data in 'The Gut Oncomicrobiome Signature of Patients with Cancer' list Clostridium boltae, C. citroniae, C. clostridioforme, C. asparagiforme, C. lavalense as overrepresented in patients with cancer, described as cancer/stress-ileopathy-driven dysbiosis rather than expansion during chronic inflammation, and the immunotherapy-compromising effect is shown only by murine gavage. So the Enterocloster attribution and the chronic-inflammation framing are not supported by this source. (LLM, conf=0.72)
- Partly supportedcites [30] Roberti, M. P. et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat. Med. 26, 919–931 (2020). sourceExperimental — accuracy not yet measured
Roberti et al. (2020) do support the generic part of the claim: in the 'Mechanisms underlying the priming of T FH cells with oxaliplatin' section they report that gavaging mice with tolerogenic commensals 'contrasting with P. clara or F. nucleatum that blunted the efficacy of the combination therapy' (OXA + anti-PD-1), and the Fig. 6h model in the Discussion ties Fusobacteriaceae/Prevotellaceae-dominated ileal microbiomes to poor αPD-1 efficacy. However, the specific taxa the citing sentence identifies — the genus Enterocloster and H. hathewayi — appear nowhere in our copy (searched: Enterocloster, Clostridium, hathewayi, enriched genera; the only Clostridia-related taxon named is Erysipeloclostridium ramosum, described as immunogenic/enriched in responders), nor is any expansion during chronic inflammation described; the work concerns ileal mucosa microbiota of proximal colon cancer patients and murine gavage/FMT models, not inflammation-driven outgrowth. So the identification of Enterocloster as an ICB-blunting bacterium is not attributable to this source. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Immunogenic versus tolerogenic microorganisms · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Various F. prausnitzii SGBs are associated with favorable prognosis in patients diagnosed with several cancer types 23,24,56”
§ Impact of the ONCOBIOME network in cancer microbiome research > Immunogenic versus tolerogenic microorganisms
What the sources say
- Partly supportedcites [23] Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315–324 (2022). sourceExperimental — accuracy not yet measured
The Discussion ('Links between fecal Akk...' / DISCUSSION) does place Faecalibacterium prausnitzii within an Akk-associated community 'associated with a health or immunogenic status' and states that Faecalibacterium, Ruminococcus and Bifidobacterium 'were previously reported to be enriched in North-American, Japanese and South Korean patients with melanoma and NSCLC cancers and have favorable outcome' — but that cross-cancer point is explicitly credited to other works (refs 17,20,41,44), and this study's own cohort is advanced NSCLC only. The claim's species-genome-bin (SGB) resolution is not supported: in our copy SGBs are used solely for Akkermansia muciniphila (SGB9223/9224/9226/9228, M&M 'Human stool samples and metagenomics analyses'), and F. prausnitzii is absent from the outcome analysis, where the bacteria associated with prolonged or reduced survival are E. hallii, B. adolescentis, P. excrementihominis, I. butyriciproducens and C. innocuum ('Stratification of clinical outcome based on other components of the Akk-associated ecosystem'). So only the generic 'Faecalibacterium prausnitzii tracks with favorable outcome' element is in this source, not multiple F. prausnitzii SGBs across several cancer types. (LLM, conf=0.70)
- Could not verifycites [24] Thomas, A. M. et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat. Med. 25, 667–678 (2019). sourceExperimental — accuracy not yet measured
Our copy of Thomas et al. (2019, Nat Med) is a case-control diagnostic meta-analysis of colorectal cancer: the Results ('A panel of microbial biomarkers for CRC is reproducible across cohorts') report differential abundance of species such as F. nucleatum, S. moorei, P. asaccharolytica, P. micra, P. stomatis and control-associated Gordonibacter pamelae/Bifidobacterium catenulatum, with no survival or prognosis endpoint anywhere (searched: 'prognosis survival patient outcome follow-up', 'Faecalibacterium prausnitzii'). Faecalibacterium prausnitzii is not named in any passage, and the only 'species-level genome bin (SGB)' mention (Results, cutC variant section) refers to an unknown Lachnospiraceae SGB ID 3957, not to F. prausnitzii SGBs. The cited paper therefore does not address the claim's point, so it can neither confirm nor contradict it. (LLM, conf=0.72)
- Partly supportedcites [56] Bredon, M. et al. Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Oncoimmunology 13, 2374954 (2024). sourceExperimental — accuracy not yet measured
Our copy supports the prognostic part at species level: the Introduction (p. n/a) states 'Several other studies also identified that high F. prausnitzii level was associated with better response to ICI in multiple cancer types', lists baseline F. prausnitzii as a predictor of ICI response in hepatocellular carcinoma and NSCLC, and reports cross-cancer strain–response signatures (crediting Gunjur et al., ref 16); its own Results show higher F. prausnitzii abundance associated with better OS in advanced NSCLC and in one of two melanoma community types. What our copy does not support is the specific unit of the claim — 'various F. prausnitzii SGBs' (species-level genome bins): no passage in our copy mentions SGBs, and the paper profiles F. prausnitzii at species level with MetaPhlAn 4 (with strain-level resolution only when summarising another study). The melanoma OS signal is also conditional (absent in the pooled whole-population analysis and in the second community type), which the citing sentence's unqualified 'favorable prognosis' does not carry. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
67 more claims · 18 with their cited sources checked
Create a free account to see all 121 claims and to verify the 113 references still open.
- It may state two separate claims as one. 46
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The TOPOSCORE is one deliverable that was developed and validated by this project.200,207”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [207]
Citations
Cites
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549 · cited 2×
“Of note, cancer-associated bacteria are also associated with other nonmalignant diseases including cardiometabolic and systemic inflammatory disorders 35 , suggesting the existence of broad shared mechanisms through which gut inflammation impacts general health 11,12,29,57–59 .”
Self-citationGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 6×
“The rationale of this trial is based on preclinical work demonstrating that strain p2261 is particularly efficient in stimulating anticancer immune responses in avatar mice that would otherwise not respond to ICB 22,23 .”
InfluentialSelf-citationAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 6×
“…as adjuvant signals mediated by microbial-associated molecular patterns acting on pattern recognition receptors expressed on host immune cells 30,48,49 ; molecular mimicry between microbial and tumor-associated antigens, resulting in cross-reactive T cell responses 55 ; the migration of immune…”
InfluentialSelf-citationThe human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464 · cited 1×
“While microorganisms invading primary tumors or metastases have been described 98–102 , the intratumoral biomass is very low and the clinical importance of these observations is often elusive.”
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Self-citationPlovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204 · cited 2×
“Adjuvant signals produced by the microbiota include lipopolysaccharide (LPS) and specific surface proteins (such as Amuc_1100 present on the surface of A. muciniphila 62 ) that act on Toll-like receptors such as TLR4 and TLR2, respectively, thus increasing the immune tonus.”
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Self-citationFecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 2×
“…of antibiotics on the efficacy of immune checkpoint blockade (ICB) 3,4 and chimeric antigen receptor (CAR) T cell therapies 5 as well as the early success of fecal microbial transplantation (FMT) and the probiotic Clostridium butyri-cum CBM 588 in patients with cancer undergoing treatment 6–10 .”
Self-citationFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Pasolli, E., Asnicar, F., Manara, S., Zolfo, M., Karcher, N., Armanini, F., Beghini, F., Manghi, P., Tett, A., Ghensi, P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.001 · Cited by 1,591
Self-citationTumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W., Quesada, P., Sahin, I., Chandra, V., San Lucas, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.008 · Cited by 1,577 · cited 1×
“While microorganisms invading primary tumors or metastases have been described 98–102 , the intratumoral biomass is very low and the clinical importance of these observations is often elusive.”
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Self-citationBlanco-Míguez, A., Beghini, F., Cumbo, F., McIver, L. J., Thompson, K. N., Zolfo, M., Manghi, P., Dubois, L., Huang, K. D., Thomas, A. M., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01688-w · Cited by 1,442 · cited 6×
“https://doi.org/10.1038/s41591-025-03608-8 taxa, exploiting a database of currently more than 1.5 million isolate genomes and metagenome-assembled genomes 15 .”
InfluentialSelf-citationThomas, A. M., Manghi, P., Asnicar, F., Pasolli, E., Armanini, F., Zolfo, M., Beghini, F., Manara, S., Karcher, N., Pozzi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0405-7 · Cited by 1,030 · cited 3×
“In this context, it appears that specific strains, species or sub-species, rather than higher-level classifications (for example, genera, phyla), acquire clinical relevance as favorable or unfavorable entities 19,23,24 .”
Self-citationDietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science · doi:10.1126/science.aaz7015 · Cited by 966
Self-citationDerosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908 · cited 1×
“…that treatment with broad-spectrum antibiotics compromises the efficacy of CTLA4 as well as PD-1–PD-L1 blockade in patients with cancer 3,22,88 , the ONC-OBIOME consortium has launched confirmatory studies as well as literature-based meta-analyses to definitively prove that antibiotics…”
Self-citationDaillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897 · cited 5×
“…as adjuvant signals mediated by microbial-associated molecular patterns acting on pattern recognition receptors expressed on host immune cells 30,48,49 ; molecular mimicry between microbial and tumor-associated antigens, resulting in cross-reactive T cell responses 55 ; the migration of immune…”
InfluentialSelf-citationLuu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24331-1 · Cited by 771
Environmental factors shaping the gut microbiome in a Dutch population
Gacesa, R., Kurilshikov, A., Vich Vila, A., Sinha, T., Klaassen, M. A. Y., Bolte, L. A., Andreu-Sánchez, S., Chen, L., Collij, V., Hu, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04567-7 · Cited by 735 · cited 2×
“Patients diagnosed with various cancer subtypes share several GOMS with individuals who have seemingly unrelated chronic inflammatory disorders 35 who, in turn, tend to have GOMS different from those of healthy donors.”
Bender, M. J., McPherson, A. C., Phelps, C. M., Pandey, S. P., Laughlin, C. R., Shapira, J. H., Medina Sanchez, L., Rana, M., Richie, T. G., Mims, T. S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.011 · Cited by 732 · cited 1×
“…cross-reactive T cell responses 55 ; the migration of immune cells from the gut to the tumor 39,63,64 ; and the production of gut microbial metabolites (polyamines 58,65–67 , short-chain fatty acids 68–71 , indoles 72–75 , vitamins 76–79 , bile acids 80,81 ) that impact the cancer–immunity dialog.”
He, Y., Fu, L., Li, Y., Wang, W., Gong, M., Zhang, J., Dong, X., Huang, J., Wang, Q., Mackay, C. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.002 · Cited by 729
Derosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01655-5 · Cited by 685 · cited 6×
“The rationale of this trial is based on preclinical work demonstrating that strain p2261 is particularly efficient in stimulating anticancer immune responses in avatar mice that would otherwise not respond to ICB 22,23 .”
InfluentialSelf-citationHealthspan and lifespan extension by fecal microbiota transplantation into progeroid mice
Bárcena, C., Valdés-Mas, R., Mayoral, P., Garabaya, C., Durand, S., Rodríguez, F., Fernández-García, M. T., Salazar, N., Nogacka, A. M., Garatachea, N., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0504-5 · Cited by 661
Self-citationMulti-omics analyses of radiation survivors identify radioprotective microbes and metabolites
Guo, H., Chou, W.-C., Lai, Y., Liang, K., Tam, J. W., Brickey, W. J., Chen, L., Montgomery, N. D., Li, X., Bohannon, L. M., et al. (2020) · Science · doi:10.1126/science.aay9097 · Cited by 561 · cited 1×
“…relying on chemotherapy, radiotherapy and hormonotherapy has not been affected by the surging awareness of the impact of the gut microbiota on immunotherapy outcome, likely because retrospective multivariate analyses indicate that antimicrobial agents do not affect chemotherapeutic outcome 74–76 .”
Caloric restriction mimetics enhance anticancer immunosurveillance
Pietrocola, F., Pol, J., Vacchelli, E., Rao, S., Enot, D. P., Baracco, E. E., Levesque, S., Castoldi, F., Jacquelot, N., Yamazaki, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.016 · Cited by 542 · cited 3×
“Other metabolites include polyamines such as spermidine, which favorably affects cancer cell immunogenicity 65 , renewal of tissue-resident T memory cells 66 and T cell effector metabolism at the level of fatty acid oxidation 67 .”
Self-citationEmbracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions
Narunsky-Haziza, L., Sepich-Poore, G. D., Livyatan, I., Asraf, O., Martino, C., Nejman, D., Gavert, N., Stajich, J. E., Amit, G., González, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.005 · Cited by 538
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
Ferrere, G., Tidjani Alou, M., Liu, P., Goubet, A.-G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillère, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145207 · Cited by 533
Self-citationFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526 · cited 6×
“Routy et al. concluded a phase 1 trial evaluating the capacity of FMT from healthy donors to improve the clinical outcome of the PD-1 inhibitors nivolumab or pembrolizumab in 20 treatment-naive patients with metastatic melanoma 20 .”
InfluentialSelf-citationThe gut microbiota influences anticancer immunosurveillance and general health
Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523
Self-citationDizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515
Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer
Jia, D., Wang, Q., Qi, Y., Jiang, Y., He, J., Lin, Y., Sun, Y., Xu, J., Chen, W., Fan, L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.022 · Cited by 479
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Tintelnot, J., Xu, Y., Lesker, T. R., Schönlein, M., Konczalla, L., Giannou, A. D., Pelczar, P., Kylies, D., Puelles, V. G., Bielecka, A. A., et al. (2023) · Nature · doi:10.1038/s41586-023-05728-y · Cited by 478
McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01698-2 · Cited by 472 · cited 3×
“…melanoma facilitated the development of the ONCOBIOME computational analysis pipeline, corroborating a strong link between the gut microbiome and progression-free survival, but revealed limited reproducibility of metastatic melanoma GOMS across distinct publicly available datasets 19,38 .”
Self-citationLee, K. A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01695-5 · Cited by 464
Self-citationTranslocation and dissemination of commensal bacteria in post-stroke infection
Stanley, D., Mason, L. J., Mackin, K. E., Srikhanta, Y. N., Lyras, D., Prakash, M. D., Nurgali, K., Venegas, A., Hill, M. D., Moore, R. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4194 · Cited by 464
A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche
Zepeda-Rivera, M., Minot, S. S., Bouzek, H., Wu, H., Blanco-Míguez, A., Manghi, P., Jones, D. S., LaCourse, K. D., Wu, Y., McMahon, E. F., et al. (2024) · Nature · doi:10.1038/s41586-024-07182-w · Cited by 451 · cited 9×
“ONCOBIOME specifically addressed the clinical relevance of the ileal microbiota in CRC.”
InfluentialSelf-citationThe Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
Zeng, M. Y., Cisalpino, D., Varadarajan, S., Hellman, J., Warren, H. S., Cascalho, M., Inohara, N., & Núñez, G. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.006 · Cited by 417 · cited 1×
“…for microbial antigens subserve various functions including preventing the outgrowth of pathogens, maintenance of systemic homeostasis during bacteremia with Gram-negative commensals 43 and boosting the efficacy of immune checkpoint inhibitors in urothelial cancers infected by bacteria 44,45 .”
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396
Self-citationKang, X., Liu, C., Ding, Y., Ni, Y., Ji, F., Lau, H. C. H., Jiang, L., Sung, J. J., Wong, S. H., & Yu, J. (2023) · Gut · doi:10.1136/gutjnl-2023-330291 · Cited by 394
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349 · cited 1×
“…the deleterious impact of antibiotics on the efficacy of immune checkpoint blockade (ICB) 3,4 and chimeric antigen receptor (CAR) T cell therapies 5 as well as the early success of fecal microbial transplantation (FMT) and the probiotic Clostridium butyri-cum CBM 588 in patients with cancer…”
Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001361 · Cited by 275 · cited 1×
“…between broad-spectrum antibiotic use and prognosis was, at least initially, independent of possible confounding factors including age, performance status and comorbidities 3,4 and was observed in patients receiving immunotherapy-based regimens but not in those receiving chemotherapy alone 91,92 .”
Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0808 · Cited by 250 · cited 2×
“Transfer of feces from patients before and after FMT 50 into avatar mice as well as dietary interventions 51,52 , administration of immunogenic live biotherapeutics 22,30,48,49,53 , specific metabolites 52 or vaccination with ileal enteroids admixed with tolerogenic or immunogenic commensals 30…”
Self-citationA core microbiome signature as an indicator of health
Wu, G., Xu, T., Zhao, N., Lam, Y. Y., Ding, X., Wei, D., Fan, J., Shi, Y., Li, X., Li, M., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.019 · Cited by 250
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
Fidelle, M., Rauber, C., Alves Costa Silva, C., Tian, A.-L., Lahmar, I., de La Varende, A.-L. M., Zhao, L., Thelemaque, C., Lebhar, I., Messaoudene, M., et al. (2023) · Science · doi:10.1126/science.abo2296 · Cited by 243
Self-citationSpermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice
Al-Habsi, M., Chamoto, K., Matsumoto, K., Nomura, N., Zhang, B., Sugiura, Y., Sonomura, K., Maharani, A., Nakajima, Y., Wu, Y., et al. (2022) · Science · doi:10.1126/science.abj3510 · Cited by 223 · cited 2×
“Other metabolites include polyamines such as spermidine, which favorably affects cancer cell immunogenicity 65 , renewal of tissue-resident T memory cells 66 and T cell effector metabolism at the level of fatty acid oxidation 67 .”
A pan-cancer analysis of the microbiome in metastatic cancer
Battaglia, T. W., Mimpen, I. L., Traets, J. J. H., van Hoeck, A., Zeverijn, L. J., Geurts, B. S., de Wit, G. F., Noë, M., Hofland, I., Vos, J. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.021 · Cited by 218
Roberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0882-8 · Cited by 208
Self-citationDiversity and dynamism of IgA−microbiota interactions
Huus, K. E., Petersen, C., & Finlay, B. B. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00506-1 · Cited by 198 · cited 1×
“Immunoglobulin proteins, specifically those from the dimeric secretory IgA class, are present in feces; they modulate bacterial colonization and gene expression in a context-dependent manner to assure homeostasis of the host and its microbiota 41 .”
Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
Self-citationTumor microbiome links cellular programs and immunity in pancreatic cancer
Ghaddar, B., Biswas, A., Harris, C., Omary, M. B., Carpizo, D. R., Blaser, M. J., & De, S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.009 · Cited by 181
Bile acid synthesis impedes tumor-specific T cell responses during liver cancer
Varanasi, S. K., Chen, D., Liu, Y., Johnson, M. A., Miller, C. M., Ganguly, S., Lande, K., LaPorta, M. A., Hoffmann, F. A., Mann, T. H., et al. (2025) · Science · doi:10.1126/science.adl4100 · Cited by 177 · cited 2×
“…cross-reactive T cell responses 55 ; the migration of immune cells from the gut to the tumor 39,63,64 ; and the production of gut microbial metabolites (polyamines 58,65–67 , short-chain fatty acids 68–71 , indoles 72–75 , vitamins 76–79 , bile acids 80,81 ) that impact the cancer–immunity dialog.”
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A. M., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00784-1 · Cited by 172 · cited 2×
“…that eight cycles of cytotoxic agents were associated with increased α -diversity and a more favorable balance between healthy ( Archaea , Dorea spp.) and inflammatory or immunosuppressive (such as E. asparagiformis , Bacteroides uniformis , Eggerthella lenta , Veillonella spp.) microorganisms 14 .”
Self-citationMicrobiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Self-citationGrajeda-Iglesias, C., Durand, S., Daillère, R., Iribarren, K., Lemaitre, F., Derosa, L., Aprahamian, F., Bossut, N., Nirmalathasan, N., Madeo, F., et al. (2021) · Aging · doi:10.18632/aging.202739 · Cited by 161
Self-citationKarcher, N., Nigro, E., Punčochář, M., Blanco-Míguez, A., Ciciani, M., Manghi, P., Zolfo, M., Cumbo, F., Manara, S., Golzato, D., et al. (2021) · Genome Biology · doi:10.1186/s13059-021-02427-7 · Cited by 159
Self-citationLongitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02803-3 · Cited by 156 · cited 1×
“We anticipate that longitudinal studies 84 involving the taxonomic and functional characterization of the microbiota at several time points (for instance, before and after treat-ment initiation, at remission and relapse) will be particularly informative to nail down small microbial communities such…”
Self-citationVitamin D regulates microbiome-dependent cancer immunity
Giampazolias, E., Pereira da Costa, M., Lam, K. C., Lim, K. H. J., Cardoso, A., Piot, C., Chakravarty, P., Blasche, S., Patel, S., Biram, A., et al. (2024) · Science · doi:10.1126/science.adh7954 · Cited by 151
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141 · cited 2×
“By contrast, fecal detection of oral taxa, species from the immunosuppressive Enterocloster genus or Hungatella hathewayi was associated with therapeutic resistance 36 .”
Self-citationImmunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17644-0 · Cited by 138
Self-citationChinese gut microbiota and its associations with staple food type, ethnicity, and urbanization
Lu, J., Zhang, L., Zhai, Q., Zhao, J., Zhang, H., Lee, Y. K., Lu, W., Li, M., & Chen, W. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00245-0 · Cited by 121
Yonekura, S., Terrisse, S., Alves Costa Silva, C., Lafarge, A., Iebba, V., Ferrere, G., Goubet, A.-G., Fahrner, J.-E., Lahmar, I., Ueda, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0999 · Cited by 112 · cited 7×
“Such Enterocloster spp. are also overrepresented in stools of patients with malignant disease or various chronic inflammatory disorders (compared with healthy donors) 29,39,40 .”
InfluentialSelf-citationTarallo, S., Ferrero, G., Gallo, G., Francavilla, A., Clerico, G. F., Luc, A. R., Manghi, P., Thomas, A. M., Vineis, P., Segata, N., et al. (2019) · mSystems · doi:10.1128/msystems.00289-19 · Cited by 111
Self-citationEbrahimi, H., Dizman, N., Meza, L., Malhotra, J., Li, X., Dorff, T., Frankel, P., Llamas-Quitiquit, M., Hsu, J., Zengin, Z. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03086-4 · Cited by 109
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Self-citationGoubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0201 · Cited by 86
Self-citationPardini, B., Ferrero, G., Tarallo, S., Gallo, G., Francavilla, A., Licheri, N., Trompetto, M., Clerico, G. F., Senore, C., Peyre, S., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.037 · Cited by 85
Self-citationFidelle, M., Yonekura, S., Picard, M., Cogdill, A., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 81
Self-citationTerrisse, S., Goubet, A.-G., Ueda, K., Thomas, A. M., Quiniou, V., Thelemaque, C., Dunsmore, G., Clave, E., Gamat-Huber, M., Yonekura, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004191 · Cited by 80
Self-citationA dynamic atlas of immunocyte migration from the gut
Galván-Peña, S., Zhu, Y., Hanna, B. S., Mathis, D., & Benoist, C. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi0672 · Cited by 74
Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors
Bredon, M., Danne, C., Pham, H. P., Ruffié, P., Bessede, A., Rolhion, N., Creusot, L., Brot, L., Alonso, I., Langella, P., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2374954 · Cited by 74
Self-citationElkrief, A., Méndez-Salazar, E. O., Maillou, J., Vanderbilt, C. M., Gogia, P., Desilets, A., Messaoudene, M., Kelly, D., Ladanyi, M., Hellmann, M. D., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00630-w · Cited by 68
Self-citationChen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.010 · Cited by 67 · cited 4×
“…immunogenic cell death in ileal crypts and to distinguish immunogenic and tolerogenic bacteria during ileal crypt apoptosis 30 as well as to analyze the effects of low-dose intestinal irradiation 94 or β-adrenergic signaling on the secretion of antimicrobial peptides by ileal enteroids 29 .”
InfluentialSelf-citationAdjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial
Bol, K. F., Schreibelt, G., Bloemendal, M., van Willigen, W. W., Bree, S. H.-D., de Goede, A. L., de Boer, A. J., Bos, K., Boer, T. D., Nordkamp, M. A. M. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45358-0 · Cited by 66
Self-citationLøfling, L. L., Støer, N. C., Sloan, E. K., Chang, A., Gandini, S., Ursin, G., & Botteri, E. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01891-7 · Cited by 59
Di Luccia, B., Molgora, M., Khantakova, D., Jaeger, N., Chang, H.-W., Czepielewski, R. S., Helmink, B. A., Onufer, E. J., Fachi, J. L., Bhattarai, B., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi5374 · Cited by 59 · cited 4×
“TREM2 blockade increased pro-inflammatory macrophages in the lamina propria, culminating in the relative dominance of Mediterraneibacter gnavus and the emigration of TNF + CD4 + T cells into tumors 64 .”
InfluentialVitamin B12 is a limiting factor for induced cellular plasticity and tissue repair
Kovatcheva, M., Melendez, E., Chondronasiou, D., Pietrocola, F., Bernad, R., Caballe, A., Junza, A., Capellades, J., Holguín-Horcajo, A., Prats, N., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00916-6 · Cited by 58
Self-citationBodywide ecological interventions on cancer
Kroemer, G., McQuade, J. L., Mérad, M., André, F., & Zitvogel, L. (2023) · Nature Medicine · doi:10.1038/s41591-022-02193-4 · Cited by 57
Self-citationHøgh, R. I., Møller, S. H., Jepsen, S. D., Mellergaard, M., Lund, A., Pejtersen, M., Fitzner, E., Andresen, L., & Skov, S. (2020) · The FASEB Journal · doi:10.1096/fj.202000162r · Cited by 56
Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis
Caparica, R., Bruzzone, M., Agostinetto, E., Angelis, C. D., Fêde, Â., Ceppi, M., & de Azambuja, E. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100066 · Cited by 56
Multifaceted modes of action of the anticancer probiotic Enterococcus hirae
Goubet, A.-G., Wheeler, R., Fluckiger, A., Qu, B., Lemaître, F., Iribarren, K., Mondragón, L., Tidjani Alou, M., Pizzato, E., Durand, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00753-8 · Cited by 54 · cited 2×
“For example, an E. hirae strain carrying a prophage from the Siphoviridae family translocates to mLNs and the spleen and boosts the T cell-dependent efficacy of cyclophosphamide or PD-1 blockade by molecular mimicry with a tumor oncogenic product 49,53,55 (Fig.”
Self-citationZhou, J., Huang, G., Wong, W.-C., Hu, D., Zhu, J.-W., Li, R., & Zhou, H. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968729 · Cited by 52
Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer
Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S. S., Liu, M., Liang, S., John, E. M., Gomez, S. L., Telli, M. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37636-0 · Cited by 49
Kim, C. G., Koh, J.-Y., Shin, S.-J., Shin, J.-H., Hong, M., Chung, H. C., Rha, S. Y., Kim, H. S., Lee, C.-K., Lee, J. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101251 · Cited by 45
Proof of Concept of Culturomics Use of Time of Care
Naud, S., Khelaifia, S., Fonkou, M. D. M., Dione, N., Lagier, J., & Raoult, D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.524769 · Cited by 39
Ciccarese, C., Porcari, S., Buti, S., Fornarini, G., Primi, F., Giudice, G. C., Damassi, A., Giron Berrios, J. R., Stumbo, L., Arduini, D., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.08.2320 · Cited by 35
Self-citationSelvanesan, B. C., Meena, K., Beck, A. P., Meheus, L., Lara, O., Rooman, I., & Gravekamp, C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001250 · Cited by 34
Alves Costa Silva, C., Piccinno, G., Suissa, D., Bourgin, M., Schreibelt, G., Durand, S., Birebent, R., Fidelle, M., Sow, C., Aprahamian, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45357-1 · Cited by 33 · cited 6×
“We obtained evidence that cancer immunotherapy not only elicits immunostimulatory metabolites but may cause an increase in immunosuppressive factors, perhaps reflecting regulatory pathways 17 .”
InfluentialSelf-citationModulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells
Elmarsafawi, A. G., Hesterberg, R. S., Fernandez, M. R., Yang, C., Darville, L. N. F., Liu, M., Koomen, J. M., Phanstiel, O., Atkins, R. M., Mullinax, J. E., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.169308 · Cited by 29
Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients
Picard, M., Yonekura, S., Slowicka, K., Petta, I., Rauber, C., Routy, B., Richard, C., Iebba, V., Tidjani Alou, M., Becharef, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00684-w · Cited by 24
Self-citationImpact of the ileal microbiota on colon cancer
Roberti, M. P., Rauber, C., Kroemer, G., & Zitvogel, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.016 · Cited by 18
Self-citationBenzodiazepines compromise the outcome of cancer immunotherapy
Montégut, L., Derosa, L., Messaoudene, M., Chen, H., Lambertucci, F., Routy, B., Zitvogel, L., Martins, I., & Kroemer, G. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2413719 · Cited by 18 · cited 1×
“Pending further confirmation in large clinical studies, such guidelines might be extended to recommend healthy diets and to warn against the use of proton pump inhibitors 95 , benzodiazepines 96 and over-the-counter probiotics 97 , which are all associated with poor immunotherapy outcome.”
Self-citationA genotype-phenotype screening system using conditionally immortalized immature dendritic cells
Zhao, L., Liu, P., Xie, W., Zhang, S., Thieme, S., Zitvogel, L., Kroemer, G., & Kepp, O. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100732 · Cited by 17
Self-citationDomzaridou, E., van Staa, T. P., Renehan, A. G., Cook, N., Welfare, W., Ashcroft, D. M., & Palin, V. (2023) · Current Oncology · doi:10.3390/curroncol30090614 · Cited by 13
From mucosal infection to successful cancer immunotherapy
Goubet, A.-G., Rouanne, M., Derosa, L., Kroemer, G., & Zitvogel, L. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00784-5 · Cited by 11
Self-citationBile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance
Fidelle, M., Tian, A.-L., Zitvogel, L., & Kroemer, G. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2224672 · Cited by 10 · cited 5×
“Such Enterocloster spp. are also overrepresented in stools of patients with malignant disease or various chronic inflammatory disorders (compared with healthy donors) 29,39,40 .”
InfluentialSelf-citationIllescas, O., Ferrero, G., Belfiore, A., Pardini, B., Tarallo, S., Ciniselli, C. M., Noci, S., Daveri, E., Signoroni, S., Cattaneo, L., et al. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.02.023 · Cited by 9
Self-citationRoberti, M. P., Picard, M., Yonekura, S., & Zitvogel, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1778834 · Cited by 6
Self-citationSzállási, Z., Prósz, A. G., Sztupinszki, Z. M., & Moldvay, J. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2324493 · Cited by 5
Fecal miRNA profiles in colorectal cancers with mucinous morphology
Naccarati, A., Dragomir, M. P., Tarallo, S., Gagliardi, A., Alberini, V., Büchler, T., Liška, V., Gallo, G., Vymetalkova, V. P., Vodičková, Ľ., et al. (2024) · Mutagenesis · doi:10.1093/mutage/geae015 · Cited by 5
Self-citationSelvanesan, B. C., Meena, K., Beck, A. P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.02.129809 · Cited by 4
Cantarelli, L., Gutiérrez Nicolás, F., García Gil, S., Morales Barrios, J. A., Oramas Rodriguez, J., & Nazco Casariego, G. J. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000494 · Cited by 4 · cited 1×
“Pending further confirmation in large clinical studies, such guidelines might be extended to recommend healthy diets and to warn against the use of proton pump inhibitors 95 , benzodiazepines 96 and over-the-counter probiotics 97 , which are all associated with poor immunotherapy outcome.”
Impact of microbiota specific circulating memory T cells in response to immunotherapy.
Gattazzo, F., Birebent, R., Lebhar, I., Xiberras, M., Marques, M., Reni, A., Flament, C., Bonato, A., Belluomini, L., Chanfreau-Paris, H., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.2024.42.16_suppl.2572 · Cited by 4
Self-citation
Cited by
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Self-citationTudorache, M., Treteanu, A. R., Pîrcălăbioru, G. G., Lixandru-Petre, I.-O., Bolocan, A., & Andronic, O. (2025) · Cancers · doi:10.3390/cancers17142294 · Cited by 20
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
Silva, C. A. C., Machaalani, M., Saliby, R. M., Zhong, C., Xie, W., Pasolli, E., Piccinno, G., Dalban, C., Fidelle, M., Meurisse, A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04067-x · Cited by 17
Self-citationBlanco, J. R., del Campo, R., Ortiz, J. A., Olmos, M. L., & Carnero, A. (2025) · Cells · doi:10.3390/cells14221813 · Cited by 14
Zhang, N., Ren, Y., & Xu, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1627949 · Cited by 24
Metadata
- Authors
- Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., Boleij, A., Bol, K., Brusselaers, N., Budinska, E., Caldas, C., Cordero, F., Cremolini, C., Daillère, R., Denkert, C., Durand, S., Ehrlich, S., Eisinger, F., Elkrief, A., Fall, K., Felder, B., Ferrere, G., Fidelle, M., Gaborit, J., Gariboldi, M., Guindo, C. O., Iebba, V., Lehtio, J., Martineau, M., Messaoudene, M., Monville, F., Naccarati, A., Pardini, B., Pinto, F., Piccinno, G., Pizzato, E., Popovici, V., Rachid, M. H., Tarallo, S., Schuler-Thurner, B., Schuler, G., Szallasi, Z., Sow, C., Trinchieri, G., Trochon, J.-J., Zeller, G., Segata, N., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre Hospitalier de l’Université de Montréal (CA)
- Goethe University Frankfurt (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Karolinska Institutet (SE)
- University of Trento (IT)
- UniCancer Group (FR)
- Radboud University Medical Center (NL)
- University of Antwerp (BE)
- Masaryk University (CZ)
- University of Cambridge (GB)
- University of Turin (IT)
- University of Pisa (IT)
- Philipps University of Marburg (DE)
- King's College London (GB)
- Institut Gustave Roussy (FR)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Italian institute for Genomic Medicine (IT)
- Leiden University (NL)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Zitvogel, Laurence
- Derosa, Lisa
- Routy, Bertrand
- Loibl, Sibylle
- Heinzerling, Lucie
- de Vries, I. Jolanda M.
- Engstrand, Lars
- Boleij, Annemarie
- Bol, Kalijn
- Caldas, Carlos
- Ehrlich, Stanislav
- Eisinger, François
- Elkrief, Arielle
- Fall, Katja
- Messaoudene, Meriem
- Piccinno, Gianmarco
- Popovici, Vlad
- Rachid, Maan Haj
- Sow, Cissé
- Trinchieri, Giorgio
- Segata, Nicola
- Kroemer, Guido
- Venue
- Nature Medicine
- Published
- 2025-04
- Volume
- 31
- Issue
- 4
- Pages
- 1085-1098
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4409370702
- Cited by
- 23
- References
- 104
- Citations by year
- 2026: 13 · 2025: 10
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Seerave Foundation (825410)
- European Commission (825410, HORIZON2020)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- gut microbiota, tumor microbiome, dysbiosis, intestinal permeability, intestinal metabolism, antitumor immunity, tumor surveillance, antibiotic-induced dysbiosis, proton pump inhibitors, clinical translation
- MeSH terms
- Gastrointestinal Microbiome, Humans, Neoplasms, Microbiota, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.